Coya Therapeutics, Inc. Common Stock (COYA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Coya Therapeutics, Inc. Common Stock (COYA) has a cash flow conversion efficiency ratio of -0.041x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.13 Million) by net assets ($27.28 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Coya Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Coya Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Coya Therapeutics, Inc. Common Stock (COYA) financial obligations for a breakdown of total debt and financial obligations.
Coya Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Coya Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nusa Raya Cipta Tbk
JK:NRCA
|
0.074x |
|
INLIF LIMITED Ordinary Shares
NASDAQ:INLF
|
-0.186x |
|
Apetit Oyj
HE:APETIT
|
0.118x |
|
Elevate Uranium Ltd
AU:EL8
|
-0.184x |
|
Hasen-Immobilien AG
STU:ABHA
|
0.010x |
|
Banco Santander Río S.A
BA:BRIO
|
-0.322x |
|
Sirtec International Co Ltd
TWO:5356
|
0.009x |
|
FitLife Brands, Inc. Common Stock
NASDAQ:FTLF
|
0.088x |
Annual Cash Flow Conversion Efficiency for Coya Therapeutics, Inc. Common Stock (2020–2024)
The table below shows the annual cash flow conversion efficiency of Coya Therapeutics, Inc. Common Stock from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see COYA market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $39.58 Million | $-10.29 Million | -0.260x | +17.20% |
| 2023-12-31 | $35.64 Million | $-11.19 Million | -0.314x | -136.40% |
| 2022-12-31 | $-8.39 Million | $-7.24 Million | 0.862x | +180.51% |
| 2021-12-31 | $3.64 Million | $-3.90 Million | -1.071x | -2172.96% |
| 2020-12-31 | $8.30 Million | $-391.27K | -0.047x | -- |
About Coya Therapeutics, Inc. Common Stock
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary therapies to enhance the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It develops COYA 302, a biologic combination for subcutaneous administration int… Read more